Can venetoclax cure leukemia?

Venetoclax (Venetoclax), an innovative targeted therapy drug, is gradually becoming an important choice for the treatment of leukemia, especially chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Although venetoclax has shown significant therapeutic effects in clinical practice, particularly in improving patient response rates, we must recognize that it does not guarantee a complete cure for leukemia.

For chronic lymphocytic leukemia (CLL), venetoclax successfully induces cancer cell apoptosis by precisely targeting the B cell lymphoma-2 (BCL-2) protein. When used in combination with other drugs, such as obinutuzumab, some patients can achieve deep remission or even complete remission. However, this does not mean that the disease has been completely cured. As a complex and easily relapsed disease, leukemia's long-term efficacy and possibility of cure still need to be verified by further clinical research.

Venetoclax also shows potential in the treatment of acute myeloid leukemia (AML). For patients who are elderly or not suitable for intensive chemotherapy, the combination of venetoclax and low-dose chemotherapy drugs, such as azacitidine (Azacitidine) or decitabine (Decitabine), has achieved higher response rates. But again, the cure rate of AML remains a difficult problem to be solved, especially in high-risk patients.

The role of venetoclax in the treatment of leukemia cannot be ignored. It can effectively extend the progression-free survival of patients, reduce the burden of cancer cells, and significantly improve the quality of life of patients. Although venetoclax can achieve complete remission in many patients, we must be soberly aware that the possibility of complete cure of leukemia is still low, especially for patients with acute leukemia. Currently, further research and clinical trials are in full swing, aiming to optimize the therapeutic effect of venetoclax or improve the cure rate through combination therapy, bringing more hope and good news to leukemia patients.